Vapotherm (NYSE:VAPO) PT Lowered to $35.00

Vapotherm (NYSE:VAPO) had its price target reduced by equities researchers at Canaccord Genuity Group from $41.00 to $35.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 103.61% from the company’s previous close.

VAPO has been the topic of several other reports. Zacks Investment Research cut Vapotherm from a “buy” rating to a “hold” rating in a research report on Tuesday, October 26th. BTIG Research reissued a “buy” rating and issued a $45.00 target price on shares of Vapotherm in a research report on Monday, September 27th. Finally, Canaccord Genuity Group dropped their target price on Vapotherm from $41.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $34.80.

VAPO opened at $17.19 on Thursday. Vapotherm has a 12-month low of $16.64 and a 12-month high of $38.46. The company has a current ratio of 3.46, a quick ratio of 2.76 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $21.20 and a two-hundred day simple moving average of $23.23. The company has a market cap of $448.19 million, a price-to-earnings ratio of -7.61 and a beta of -1.33.

Vapotherm (NYSE:VAPO) last issued its quarterly earnings results on Wednesday, November 3rd. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.02). Vapotherm had a negative net margin of 44.28% and a negative return on equity of 54.76%. The company had revenue of $38.12 million for the quarter, compared to the consensus estimate of $32.56 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. On average, analysts predict that Vapotherm will post -2.22 EPS for the current year.

In other Vapotherm news, SVP Gregoire Ramade sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 4th. The stock was sold at an average price of $25.03, for a total value of $50,060.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of VAPO. OLD Mission Capital LLC purchased a new position in shares of Vapotherm during the 3rd quarter valued at about $357,000. Advisor Group Holdings Inc. lifted its position in shares of Vapotherm by 110.5% during the 2nd quarter. Advisor Group Holdings Inc. now owns 1,987 shares of the company’s stock valued at $47,000 after buying an additional 1,043 shares in the last quarter. Swiss National Bank lifted its position in shares of Vapotherm by 7.2% during the 2nd quarter. Swiss National Bank now owns 34,100 shares of the company’s stock valued at $806,000 after buying an additional 2,300 shares in the last quarter. Sei Investments Co. lifted its position in shares of Vapotherm by 4.4% during the 2nd quarter. Sei Investments Co. now owns 32,737 shares of the company’s stock valued at $774,000 after buying an additional 1,394 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of Vapotherm by 58.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 13,392 shares of the company’s stock valued at $317,000 after buying an additional 4,937 shares in the last quarter. 70.41% of the stock is currently owned by hedge funds and other institutional investors.

Vapotherm Company Profile

Vapotherm, Inc is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter.

Featured Story: Systematic Risk

Stock Target Advisor logo

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.